Signa Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 09-12-2024
- Paid Up Capital ₹ 0.50 M
as on 09-12-2024
- Company Age 40 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.10 M
as on 09-12-2024
- Satisfied Charges ₹ 2.84 M
as on 09-12-2024
- Revenue 31.74%
(FY 2022)
- Profit 44.65%
(FY 2022)
- Ebitda -2.27%
(FY 2022)
- Net Worth 88.32%
(FY 2022)
- Total Assets -2.94%
(FY 2022)
About Signa Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹2.10 M. The company has closed loans amounting to ₹2.84 M, as per Ministry of Corporate Affairs (MCA) records.
Rekha Bhargava, Rinku Bhargava, and Saurabh Bhargava serve as directors at the Company.
- CIN/LLPIN
U24231UP1984PTC006453
- Company No.
006453
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Mar 1984
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Kanpur Nagar, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Signa Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Saurabh Bhargava  | Managing Director | 04-Oct-2011 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rekha Bhargava | Director | 01-Oct-1985 | Current |
| Rinku Bhargava | Director | 04-Oct-2011 | Current |
Financial Performance of Signa Pharma.
Signa Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 31.74% increase. The company also saw a substantial improvement in profitability, with a 44.65% increase in profit. The company's net worth Soared by an impressive increase of 88.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Signa Pharma?
Unlock access to Signa Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 06 Jul 2019 | ₹1.00 M | Open |
Others Creation Date: 07 Oct 2016 | ₹1.10 M | Open |
Punjab National Bank Creation Date: 04 Dec 2009 | ₹0.32 M | Satisfied |
How Many Employees Work at Signa Pharma?
Unlock and access historical data on people associated with Signa Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Signa Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Signa Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
